+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

HIV serum RNA levels, CD4 number and clinical outcomes in HIV infected subjects with 200 to 500 CD4 cells per cubic millimeter receiving zidovudine, with or without didanosine



HIV serum RNA levels, CD4 number and clinical outcomes in HIV infected subjects with 200 to 500 CD4 cells per cubic millimeter receiving zidovudine, with or without didanosine



Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 268-269




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 031635730

Download citation: RISBibTeXText


Related references

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. New England Journal of Medicine 335(15): 1099-1106, 1996

Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Research & Human Retroviruses 16(7): 645-653, 2000

Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. Aids Research and Human Retroviruses 16(7): 645-653, 2000

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. Aids 13(7): 851-858, 1999

Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients. Aids 14(16): 2567-2574, 2000

Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group. Annals of Internal Medicine 120(5): 360-368, 1994

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. New England Journal of Medicine 333(7): 401-407, 1995

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. New England Journal of Medicine 335(15): 1091-1098, 1996

Supplement 1. Clinical Perspectives in the Treatment of HIV Disease: The Role of Didanosine || Use of Didanosine in Zidovudine-Intolerant Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases 16: S59-S62, 1993

Determinations of zidovudine/didanosine/nevirapine and zidovudine/didanosine/ritonavir in human serum by micellar electrokinetic chromatography. Journal of Pharmaceutical & Biomedical Analysis 30(4): 955-960, 7 November, 2002

Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 17(3): 227-234, 1998

Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects. NetherlandsJournalofMedicine37(1-2):4, 1990

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. Journal of Infectious Diseases 172(1): 70-78, 1995

L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. Antioxidants and Redox Signaling 4(3): 391-403, 2002

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. New England Journal of Medicine 322(14): 941-949, 1990